Corporate Information
XOMA is a leader in the discovery, development and manufacture of therapeutic antibodies. XOMA's exceptionally broad technology platform, leading scientific expertise, and fully integrated product development infrastructure, extends from antibody discovery to regulatory approval. A proven development partner and technology licensor, XOMA receives royalties from UCB, S.A. for CIMZIA® (certolizumab pegol). Our pipeline includes an expanding number of proprietary products and collaborative programs at various stages of clinical and preclinical development.
Access XOMA 2009 Proxy Materials
Recent News
Sep 2, 2010
XOMA Regains NASDAQ Compliance
Aug 26, 2010
XOMA Appoints Jack L. Wyszomierski to Its Board of DirectorsEvents
Aug 9, 2010
XOMA Ltd. Second Quarter 2010 Financial Results Conference Call
$0.01
